Shenyang Xingqi Eye Medicine

Shenyang Xingqi Eye Medicine is a leading Chinese pharmaceutical company specializing in the research, development, production, and sale of ophthalmic drugs. The company offers a comprehensive portfolio of eye care products, including treatments for dry eye, infections, glaucoma, and inflammatory conditions. A major milestone for the company was the 2024 NMPA approval of its 0.01% atropine sulfate eye drops, the first of its kind in China for slowing the progression of myopia in children. Xingqi Eye Medicine operates advanced manufacturing facilities and maintains a strong R&D focus on innovative ophthalmic therapies. The company is publicly traded on the Shenzhen Stock Exchange and is a key player in the rapidly growing Chinese vision care market. Its product line includes various formulations such as eye drops, eye gels, and eye ointments.